Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
27 studies found for:    Threshold
Show Display Options
Rank Status Study
1 Recruiting Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: TH-302;   Drug: TH-302 and bortezomib
2 Completed Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors
Conditions: Lung Cancer;   Breast Cancer;   Pancreatic Cancer;   Head and Neck Cancer;   Gastric Cancer
Intervention: Drug: 2-deoxy-D-glucose (2DG)
3 Terminated Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Conditions: Benign Prostatic Hyperplasia;   Enlarged Prostate
Intervention: Drug: Lonidamine
4 Completed Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
Conditions: Non-Small Cell Lung Cancer;   Prostate Cancer;   Pancreatic Cancer
Intervention: Drug: TH-302
5 Active, not recruiting Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
Conditions: Advanced Renal Cell Carcinoma;   Gastrointestinal Stromal Tumors;   Pancreatic Neuroendocrine Tumors
Intervention: Drug: TH-302
6 Completed Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Drug: Glufosfamide
7 Recruiting A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: TH-302
8 Completed Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
Conditions: Neoplasms;   Pancreatic Neoplasms
Interventions: Drug: Glufosfamide;   Drug: Gemcitabine
9 Completed Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   High-risk Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Advanced Myelofibrosis
Intervention: Drug: TH-302
10 Recruiting A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: TH-302
11 Completed A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Conditions: Tumors;   Hypoxia
Intervention: Drug: TH-302
12 Completed Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Intervention: Drug: TH-302
13 Recruiting Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: TH-302 combination with pemetrexed;   Drug: Matched placebo in combination with pemetrexed
14 Terminated Safety and Efficacy Study of Glufosfamide in Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Glufosfamide
15 Terminated Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
Condition: Carcinoma, Small Cell Lung
Intervention: Drug: Glufosfamide
16 Completed Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Gemzar (Gemcitabine);   Drug: TH-302
17 Terminated Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Condition: Benign Prostatic Hyperplasia
Intervention: Drug: Lonidamine
18 Active, not recruiting A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Interventions: Drug: TH-302 in Combination with Doxorubicin;   Drug: Doxorubicin
19 Active, not recruiting Dose Escalation Study of Pazopanib Plus TH-302
Condition: Solid Tumors
Intervention: Drug: Pazopanib and TH-302
20 Not yet recruiting TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Phase I Dose level -1;   Drug: Phase I dose level 1;   Drug: Phase I Dose level 2;   Drug: Phase I Dose level 3

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Indicates status has not been verified in more than two years